Warning: count(): Parameter must be an array or an object that implements Countable in /home/logicben/public_html/drugtrialsformoney.com/wp-content/plugins/redux-framework/redux-core/inc/classes/class-redux-output.php on line 391

TAS-102 and Oxaliplatin for the Treatment of Refractory Stage IV Colon Cancer

TAS-102 and Oxaliplatin for the Treatment of Refractory Stage IV Colon Cancer
Conditions:   Metastatic Colorectal Carcinoma;   Recurrent Colon Carcinoma;   Refractory Colorectal Carcinoma;   Stage IV Colon Cancer AJCC v7;   Stage IVA Colon Cancer AJCC v7;   Stage IVB Colon Cancer AJCC v7
Interventions:   Drug: Oxaliplatin;   Drug: Trifluridine and Tipiracil Hydrochloride
Sponsors:   Rutgers, The State University of New Jersey;   National Cancer Institute (NCI)
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

March 5, 2020 / by / in
Comments